Sorrento Therapeutics Inc. (SRNE) Soars 9.06%

Sorrento Therapeutics Inc. (SRNE) had a good day on the market for Tuesday December 03 as shares jumped 9.06% to close at $3.73. About 23 million shares traded hands on 59,960 trades for the day, compared with an average daily volume of n/a shares out of a total float of 141.87 million. After opening the trading day at $3.42, shares of Sorrento Therapeutics Inc. stayed within a range of $4.00 to $3.34.

With today’s gains, Sorrento Therapeutics Inc. now has a market cap of $529.18 million. Shares of Sorrento Therapeutics Inc. have been trading within a range of $6.50 and $1.39 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates.

Sorrento Therapeutics Inc. is based out of San Diego, CA and has some 382 employees. Its CEO is Henry Ji.

Sorrento Therapeutics Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!